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Treatment of acute infectious gastroenteritis consists mainly of rehydration and rapid realimentation. However, the 
natural intestinal microflora is disrupted in both acute and chronic infectious diarrhea, resulting in complex interactions 
possibly aggravating this; frequently self-limiting condition. Therefore, additional therapeutic intervention with 
biotherapeutic agents is worth considering. The results of most randomized prospective double-blind clinical trials with 
bacterial biotherapeutic agents are disappointing, showing a lack of efficacy, except for Lactobacillus casei strain GG, 
for which both positive an’d negative results have been published. 
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INTRODUCTION 
In the USA, diarrheal diseases cause an estimated 
167 000 hospitalizations and 300 deaths each year 
among children younger than 5 years of age [l-31. 
Treatment is largely symptomatic and involves fluid and 
electrolyte replacement, and maintenance of nutrition 
[4-61. During an episode of gastroenteritis, there is a 
decrease of protective commensal microflora, followed 
by an overgrowth of urease-producing pathogenic 
bacteria [7]. Therefore, normalization of the gastro- 
intestinal microflora during an episode of acute diarrhea 
may shorten the duration of the diarrhea, make it less 
severe and improve its outcome. Although the con- 
sumption of ‘probiotics’, aa in fermented milks, dates 
from pre-biblical times, the theoretical concept of 
probiotics or biotherapy was first described by the 
Russian Metchnikov, who was awarded the Nobel 
Prize for medicine in 1908 €or demonstrating that some 
bacteria could stimulate the growth of I ?brio cholevae, 
while others inhibited its growth. 
Lactulose is an example of a prebiotic, a non- 
digestible ingredient that is beneficial for the host 
because it enhances growth and/or activity of one or 
more non-pathogenic bacterial strains in the colon [8] .  
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A biotherapeutic agent or probiotic is a live microbial 
food supplement which beneficially affects the host by 
improving the intestinal microbial balance 191. By 
definition, these microorganisms need to be prepared, 
preserved and administered in a viable form. Bio- 
therapeutic agents survive in the intestinal ecosystem. 
‘Acidophilus’ or ‘bifidus’ yoghurts are probiotic yog- 
hurts. It is proposed to use ‘probiotic’ to designate all 
products fulfilling the above criteria. The term ‘bio- 
therapeutic agent’ should only be used to designate the 
medical products (drugs) complying with the above 
definition. 
In this review, I shall discuss biotherapeutic agents 
only, and analyze the literature critically, focusing on 
kinetics, pharmacodynamics, prospective, randomized, 
placebo-controlled clinical studies testing the efficacy 
of the biotherapeutic agent against acute and chronic 
infectious diarrhea, and the side effects of biothera- 
peutic agents. Unfortunately, many review papers con- 
sider and attribute identical convincing evidence to 
case reports, and open and blind studies [lo]. Open 
trials, such as the use of Bactevoides sp. in Clostridium 
d$ficile diarrhea [ll],  are not considered in the 
discussion. 
NATURAL BACTERIAL PROBIOTICS 
Fermented milk products such as yoghurt, kefir and 
buttermilk contain living bacteria, most frequently 
Bifidobacterium bifidum, BGdobacterium longurn, L Q d O -  
bacillus acidophilus, Lactobarillus bulgnricur, Streptococcus 
lactis and Streptococcus cremoris [I?-]. The use of fer- 
mented milk products in a clinical setting is difficult 
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because of the need for cold storage and limited 
shelf-life. Also, it is difficult to persuade sick patients 
(especially the elderly or children) to consume a 
sufficiently large quantity (at least three yoghurts daily 
[13]) of yoghurt or fermented milk to make any 
clinical impact likely. The resistance of most yoghurt 
bacteria to bile and acid is poor, although differences 
between strains have been observed [14,15]. Fre- 
quently, this resistance is not mentioned [13]. Lacto- 
bacillus acidophilus survives the gastric acidity better if 
adrmnistered in milk as vehicle, than with yoghurt or 
buttermilk 1141. Even if antibiotics such as p-lactams, 
tetracyclines and quinolones are administered intra- 
venously, the hepatoenteric cycle inactivates these 
biotherapeutic agents rapidly. 
COMMERCIAL PROBIOTIC AGENT FOODS 
Some probiotic agents are registered as medicinal 
products, while others are registered as ‘food’. If 
registered as foods, products are not subjected to the 
same testing as medical products, and medical 
terminology cannot be used to describe the claimed 
effect(s). Lactobacillus acidophilus, Lactobacillus bulgaricus, 
Streptococcus thermophilus and Enterococcusfaecium SF 68 
can be purchased as viable bacteria in dried form as 
granules or capsules in health food shops, and are thus 
not available on medical prescription. Probiotic foods 
have to fulfil the criteria for the food legislation, and 
not the legislation for medical drugs. The bacteria 
present in probiotic foods are found in the normal 
human colonic flora, but are not resistant to most 
commonly used antibiotics. (An effective probiotic 
should be naturally resistant to commonly used 
antibiotics.) The labeling of many probiotic foods may 
be misleading, in terms of both their microbiological 
content and their claimed beneficial effects [ 16,171. 
Brewers’ yeast (Saccharomyces cerevisiae) is sold as a food 
supplement for human consumption for constipation, 
but is not viable. The regulations on probiotic agent 
preparations and the marketing of dairy foods con- 
taining probiotic bacteria must give better guarantees 
for the consumer on the quality of these expensive 
products [17]. 
RECTAL BIOTHERAPY 
Although theoretically interesting in patients with 
colitis, rectal biotherapy has only been investigated, over 
a period of more than 40 years, in uncontrolled studies 
and in small numbers of patients (n <30) [12,18]. The 
rectal route is difficult to manage for doctors and 
patients, and the (theoretical) risk of a spread of unde- 
tected pathogens cannot be ignored. 
KINETICS OF THE PHARMACEUTICAL BACTERIAL 
BIOTHERAPEUTIC AGENTS 
A biotherapeutic agent has to be detectable &ve in the 
entire gastrointestinal tract (thus also in feces), even 
when administered simultaneously with antibiotics, in 
numbers high enough to be effective. A biotherapeutic 
agent can only be effective if it survives contact with 
gastric and pancreatic secretions, including acid [9,12]. 
It is essential for a biotherapeutic agent that its natural 
resistance to antibiotics cannot be transferred to the 
natural colonic flora or to pathogens present in the host, 
including in the gastrointestinal tract [9], and that the 
biotherapeutic agent does not acquire the resistance of 
some commensal or pathogenic microorganism and 
subsequently transfer it to other commensal or patho- 
genic microorganisms. Most lactobacilli are lulled by 
acid and/or bile [9,12]. Only 1.5% and 37.5% of 
ingested Lactobacillus acidophilus and bifidobacteria, 
respectively, reach the ileum [19]. 
PHARMACODYNAMICS OF THE PHARMACEUTICAL 
BACTERIAL BIOTHERAPEUTIC AGENTS 
Colonization resistance 
Colonization resistance is the ability of the normal 
colonic flora to protect the host against colonization by 
pathogens, and is achieved via a complex interaction 
between the various strains. A biotherapeutic agent is 
intended to inhibit the proliferation of pathogens 
during a period when the normal colonic microflora is 
disturbed [9]. At present, no single bacterium or com- 
bination of bacteria is capable of inducing colonization 
resistance to pathogens in a sirmlar way to the natural 
colonic microflora [9]. 
Production of antibacterial substances 
In vitro, Lactobacillus casei strain GG inhibits the growth 
of Gram-positive and Gram-negative bacteria, and 
produces hydrogen peroxide, which has a bactericidal 
effect, together with other inhibitory metabolic pro- 
ducts [9]. However, it is not clear whether these anti- 
bacterial substances are also effective in vivo, although 
they are reported to be so in animal models with 
Lactobacillus acidophilus strain LA1 and Lactobacillus casei 
strain GG [9,20-221. In vitro, yoghurt with Streptococcus 
thermophilus and Lactobacillus bulgaricus is bactericidal for 
Clostridium d@cile within 2 h [20]. However, in vivo, 
hamsters are not protected from death by Clostridiurn 
d@cile-induced colitis, even if very large amounts of 
yoghurt have been administered [20]. 
Competition for nutrients 
Growth of Clostridium d@cile depends on the availability 
of monosaccharides. Increased competition in vivo for 
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monosaccharides inhibits Ci’ostridium dficile growth, 
while an increased supply of them stimulates its growth 
[23]. Little is known about ithe influence of bacterial 
biotherapeutic agents on nutrient competition. 
Competitive inhibition at bacterial adhesion sites 
Competitive inhibition by the biotherapeutic agent at  
the adhesion sites for bacterial pathogens is another 
interesting possible mechanism of action [9]. Certain 
Lactobacillus acidophilus strains, such as LA1, compete in 
vitro for cell adhesion to and/or invasion of enterocyte- 
like cells with enteropathogeruc Escherichia coli, Salmon- 
ella typhimurium and Rrsinia pseudotuberculosis [24]. The 
Lactobacillus acidophilus LB wain produces antibacterial 
activity in vitro against Staphylococcus aureus, Listeria 
monocytogenes, Salmonella typliimurium, Shigella Jexneri, 
Escliericliia coli, Klebsiella ptjeumoniae, Bacillus cereus, 
Pseudomonas aeruginosa and Enterobacter spp. [21]. In 
contrast, there is no inhibition of lactobacilli and bifido- 
bacteria [21]. However, if Escherichia coli is administered 
before the Lactobacillus acidopliilus (as occurs when acute 
gastroenteritis is treated with, a biotherapeutic agent), 
the protection by the Lactobacillus strain is severely 
reduced, because of non-specific steric hindrance of the 
receptor sites [21]. ‘Heat-kilkd’ Lactobacillrts acidopliilus 
was demonstrated in vitro to retain adhesion capacity, 
although it was not viable [25,26]. However, even in 
vitro, 10 times the amount of heat-killed Lactobacillirs 
acidophilus than of the living strain was required to obtain 
the same prevention of adhesion of enterotoxic 
Escherichia coli [25]. Even more unrealistic concentra- 
tions are needed to obtain a preventive effect in vivo 
[25]. Viable lactobacdli failed to prevent or change the 
duration or symptoms of enterotoxic Escherichia coli 
diarrhea in adults [27]. Viable Lactobacillus acidophilus 
preparations are not effective in the prevention of 
travelers’ diarrhea [28,29], although enterotoxic 
Escherichia coli is the most important (40%) causal organ- 
ism [30]. Lactobacillus salii,arius inhibits colonization of 
the stomach with Helicobacter pylori in gnotobiotic 
BALB/c and germ-free mice [31]. 
As a consequence, the relevance of competitive 
inhibition for adhesion sites is restricted to prevention, 
since in therapeutic conditions the adhesion of the 
pathogen has already taken phce. The clinical relevance 
of the in vitro model, in which the preventive 
administration of lactobacilli competes with the adhe- 
sion of enteropathogens, andl especially of enterotoxic 
Eschericlzia coli, is thrown into question by the dis- 
appointing clinical results. 
Enhancement of the immune defense system 
Children with rotavirus diarrhea secreted signifi- 
cantly more rotavirus-specific IgA cells during the 
convalescence period if a living rather than a heat- 
killed Lactobacillits casei strain GG was administered 
[32]. During the diarrhea period itself, rotavirus- 
specific antibodies were similar and very low in both 
groups, and there was no  difference in the duration 
of diarrhea observed [32]. The increased specific 
antibody production occurred at a later stage, and is 
(probably) relevant in the prevention of reinfection 
[ 3 2 ] .  These data have been confirmed in a similar 
study, showing that Lactobacillus casei strain GG is 
more effective than Lactobacillus casei rhamnosirs or a 
combined lactobacillus preparation [33]. The en- 
hancement of the immune system by the admin- 
istration of lactobacilli during a rotavirus infection 
might be relevant in the prevention of reinfection, 
but does not influence the acute phase. Lactobacillus 
casei strain GG has an immunostimulating effect on 
oral rotavirus vaccination [34]. Lactobacillus casei strain 
GG has the potential to increase the gut IgA immune 
response and promotes the gut immunologic barrier 
in patients with Crohn’s disease [35]. Lactobacillus 
reuteri prevents Cryptosporidium parvum infection in 
immunodeficient mice [36]. 
RANDOMIZED DOUBLE-BLIND STUDIES WITH 
PHARMACEUTICAL BACTERIAL BIOTHERAPEUTIC 
AGENTS (TABLE 1) 
Lactobacillus acidophilus 
Different types of Lactobacillus acidophilus preparation 
have been tested in double-blind placebo-controlled 
studies. Although Lactobacillirs rhamnosus is present in 
some products, it has not been clinically evaluated. A 
‘dried’ (freeze-dried?) combination of Lactobacilliis 
acidophilus and Lactobacillus bukaricus has been tested 
for the prevention of Escherichia coli diarrhea, of 
travelers’ diarrhea, of amoxycillin-associated diarrhea 
and of diarrhea during enteral feeding [27,28,37]. 
The  symptoms and duration of diarrhea with 
enterotoxic Escherichia coli remained unchanged, even 
if Lactobacillus acidophilus and Lactobacillus bulgaricus had 
been administered prophylactically, 36 h before the 
Escherichia coli [27]. The same combination also failed 
to show any effect in the prevention of travelers’ 
diarrhea, antibiotic-associated diarrhea and enteral 
feeding-associated diarrhea [28,37,38]. Viable Lacto- 
bacillus acidophilus was tested, without success, in the 
prevention of travelers’ diarrhea [29,39]. A heat-killed 
Lactobacillus acidophilus strain was evaluated in a 
double-blind placebo-controlled study in the treat- 
ment of acute diarrhea [40]. All these studies failed to 
demonstrate any significant difference between the 
Lactobacillus acidophilus and the placebo groups. 
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Table 1 Randomized double-blind studies with bacterial biotherapeutic agents 
Clinical 
Study Biotherapeutic outcome 
Reference population Indication agent p-value 
95 94 
27 48 
28 50 
38 38 
37 35 
29 319 
39 202 
40 71 
41 820 
42 71 
45 20 
47 287 
101 
186 
44 32 
49 16 
51 39 
53 17 
48 123 
96 39 
26 
39 181 
54 14 
55 45 
55 78 
56 114 
56 39 
57 97 
58 40 
59 55 
60 30 
61 143 
97 11  
Acute diarrhea in infants 
Diarrhea in ETEC-infected volunteers 
Travelers' diarrhea 
Amoxycdhn-associated darrhea 
Enteral feeding-associated diarrhea 
Travelers' diarrhea 
Travelers' diarrhea 
Acute diarrhea in children 
Travelers' darrhea 
Acute diarrhea 
Enteral feedmg in prematures 
Duration of diarrhea in children 
Duration of diarrhea if rotavirus positive 
Duration of diarrhea if rotavirus negative 
Non-bloody acute diarrhea 
Erythromycin-associated diarrhea 
Clostridium dtjicile colitis 
Atopic dermatitis with elimination diet 
Acute diarrhea 
Acute diarrhea in children 
Non-bloody diarrhea 
Travelers' dmrhea 
Bacterial overgrowth 
Antibiotic-associated diarrhea 
Acute diarrhea 
Duration of Kbria cholerae diarrhea 
Duration of Escherichia coli darrhea 
Duration of rotavirus darrhea 
Duration of rotavirus diarrhea 
Prevention of diarrhea 
Prevention of diarrhea 
Prevention of diarrhea 
Chronic abdominal pain 
Streptococcus thermophilus 
Streptocouus lactis 
Lactobm'llus m'dophilus 
Lactobm'llus bulgaricus 
Lactobacillus bulgaricus 
Lactobacillus acidophilus 
Lactobacillus bulgaricus 
Lactobacillus m'dophilus 
Lactobacillus bulgaricus 
Lactobacillus acidophilus 
Lactobacillus bulgarincs 
Lactobacillus m'dophilus 
Lactobacillus acidophilus 
Lactobacillus m'dophilus 
(heat killed) 
Lactobacillus m'dophilus 
Lactobm'llus GG 
Lactobacillus GG 
Lactobacillus GG 
Latobatillus GG 
Lactobacillus GG 
Lactobacillus GG 
Lactobacillus GG 
Lactobacillus GG 
Lactobacillus GG 
Lactobacillus fermenturn 
Lactobacillus fermentum 
Enterococcus faecium SF 68 
Enterococcusfaecium SF 68 
Enterococcusfaecium SF 68 
Enterococcus faecium SF 68 
Lactobacillus reuteri 
Lactobm'llus reuteri 
Streptococcus thermophilus 
Bifdobacterium bifdum 
Bifdobacterium bifdum 
Lactobacillus plantarum 299 V 
Lactobacillus plantarum 299 V 
Lactobacirrus GG 
Lactobm'rrus GG 
Lactobacirrus GG 
Lactobacirrus GG 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
<0.001 
NS 
NS 
<0.05 
NS 
<0.01 
<0.05 
<0.001 
c0.05 
NS 
NS 
0.055 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
0.035 
NS 
NS 
NS 
ETEC, enterotoxic Escherichia coli; NS, not statistically significant. 
l8ctob8ci//us cesei strain GG 
Lactobacillus casei strain GG was evaluated in a pro- 
spective randomized placebo-controlled study in 880 
volunteers for the prevention of travelers' diarrhea, 
showing a non-significant effective trend in the Lacto- 
bacillus casei strain GG group (p=0.07) [41]. In a sub- 
group of less than 200 patients visiting a particular area 
of Turkey, significant protection was observed, albeit 
only during the first week [41]. In contrast, at another 
location, a higher incidence of diarrhea was observed 
in the Lactobacillus casei strain GG group, making it 
difficult to draw firm conclusions [41]. The etiology of 
the diarrhea at the various destinations was not 
investigated [41]. Lactobacillus casei strain GG was shown 
to be effective in recovery from acute rotavirus diarrhea 
in children [42,43] and in non-bloody diarrhea of 
undetermined etiology [44], by decreasing the duration 
of diarrhea. There was no effect of Lactobacillus casei 
strain GG on the clinical outcome of premature infants 
who were enterally fed [45], although Lactobacillus casei 
strain GG did colonize the intestine [45,46]. The 
administration of Lactobacillus casei strain GG in oral 
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rehydration solution tends to reduce the duration of 
diarrhea, although this effect seems to be limited to 
rotavirus-positive gastroenteritis [47], and could not be 
confirmed [48]. Lactobacillus casei strain GG may also 
decrease the duration of antibiotic-associated diarrhea 
[49]. Lactobacillus cusei strain GrG has also been reported 
to be effective in Clostridiuwi drficile colitis [50-521. 
Finally, the addition of Lactob(aci1lus casei strain GG to a 
cows’ milk elimination diet in children with atopic 
dermatitis and food allergy promotes endogenous 
barrier mechanisms by alleviating intestinal inflam- 
mation, and results in a significant additional decrease 
of the eczema [53]. 
Lactobacillus fennentum (KLD strain) 
Lactobacillus fermenturn is a bac:terium belonging to the 
natural colonic microflora, resistant to acid, and adher- 
ing to enterocytes [39]. However, no protection against 
travelers’ harrhea could be demonstrated [39]. Also, 
there was no effect on the hydrogen breath test, symp- 
tom score and number of defecations in patients with 
bacterial overgrowth [54]. 
Enterococcus faecium SF68 
Several randomized double- blind studies have been 
carried out with Enterococcus faecium SF68 [55,56]. 
Enterococcus faecium SF68 was effective in the treat- 
ment of acute diarrhoea of unspecified etiology [55]. 
A preventive effect of Enterococcusfaecium on antibiotic- 
associated diarrhea was suggested, but the number of 
patients included was too small (45) to demonstrate a 
significant difference (p=O.l’l) [55]. In a large popul- 
ation of adult patients with proven Vibrio cholerae or 
enterotoxic Escherichia coli diarrhea, no effect on the 
volume and duration of diarrhea was found [56]. A 
possible explanation for the absence of any effect may 
be that Enterococcusfaecium SF68 is unable to inhibit the 
growth of both pathogens in the gastrointestinal tract 
~561. 
Lactobacillus reuteri 
Lactobacillus reuteri in high dose (lo1’ or 10” colony- 
forming units) or low dose (10’ colony-forming units), 
or placebo (lactose), was administered to children with 
rotavirus diarrhea [57,58]. Nhough the number of 
children with watery stools on day 2 was significantly 
reduced in the Lactobacillus reuteri group, there was no 
effect on the duration of the diarrheal episode [58]. The 
main effect of Lactobacillus reuteri was on the duration of 
the diarrhea, with a correlation between the dosage and 
the clinical effect [57]. However, it should be ques- 
tioned whether lactose should be given as placebo, 
because of the possible secondary deficiency in lactase 
activity [57]. 
Prepared milk food with Streptococcus tkermophilus 
and/or Bifidobacterium bifidum, or Lactobacillus 
plantarium 299V 
A locally prepared infant formula with Streptococcus 
thermophilus and Bijdobacterium b i jdum had a statistically 
significant effect on the prevention of diarrhea occur- 
ring in a ward with chronically sick children, 5-24 
months old [59]. The incidence of rotavirus diarrhea 
also tended to be reduced [59]. However, in a sirmlarly 
designed study including only Bijdobacterium bijidum as 
biotherapeutic agent, there was no difference in the 
number of infants with diarrhea or in the number of 
diarrhea episodes [60]. In this study, the duration of 
diarrhea was less in the group receiving the biother- 
apeutic agent (1.2 versus 2.3 days) [60]. Lactobacillus 
plantarum 299 V given daily in a fermented oatmeal 
powder failed to reduce the incidence of diarrhea in a 
day-care facility [61]. 
Baci/Ius cereus IP 5832 and Bacillus subtilis 
Although only a few case reports can be found in the 
literature between 1950 and today, Bacillus cereus IP 
5832 and Bacillus subtilis have been widely used in 
France and Belgium, without any proof of benefit [62]. 
A combination of four Bacillus subtilis strains, resistant 
to most antibiotics, has been developed, but has not 
been thoroughly evaluated [63]. 
SIDE EFFECTS OF PHARMACEUTICAL BACTERIAL 
BIOTHERAPEUTIC AGENTS 
Malabsorption and metabolic acidosis 
The addition of viable Lactobacillus acidophilus to milk 
does not improve the digestion of lactose: milk to 
which Lactobacillus acidophilus is added causes the same 
degree of malabsorption in lactase-deficient consumers 
as ordinary milk [64,65]. After ingestion of lactobacilli 
in lactase-deficient patients, large numbers of the 
microorganisms are discovered in the colonic flora, but 
without any effect on lactose malabsorption [65,66]. 
Some lactobacillus preparations contain small amounts 
of lactose; administration of these products is not 
indicated in lactose intolerance. It seems undesirable to 
administer small amounts of extra lactose in the 
treatment of acute infectious gastroenteritis, a disease 
possibly compromising the lactase activity. 
Disturbances in the subtle balance between Gram- 
positive and Gram-negative bacteria in the natural 
colonic flora may be induced by the administration 
of Gram-positive bacteria such as lactobacilli and 
bifidobacteria, which grow more rapidly than Gram- 
negative bacteria. This disequilibrium may result in 
metabolic D-lactate acidosis, as a consequence of the 
bacterial carbohydrate metabolism [67]. Gram-positive 
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overgrowth may occur in many situations, including 
anatomic or functional short bowel, antibiotic treat- 
ment, exclusive feeding with dairy products, excessive 
presence of carbohydrates in the diet, and/or the use of 
oral Lactobacillus acidophilus tablets [67-711. 
Bacteremia 
Endocarditis, meningitis, pneumonia and sepsis have 
been reported with lactobacilli [33,72,73]. Also, 
indigenous bacteria, not those introduced by a bio- 
therapeutic agent, have been indentified as causative 
factors in endocarditis [74,75]. In case reports, lactic 
acid bacteria are also mentioned as causing local infec- 
tions such as chest infections, digestive tract infections, 
urinary tract infections and meningitis [76]. In Finland, 
among 3317 blood culture isolates, lactobacilli were 
identified in eight patients [77]. None of them was 
caused by Lactobacillus casei strain GG [77,78]. Although 
the pathogenic potential of bacterial biotherapeutic 
agents is low, it does exists [77]. Enterococci are a 
known cause of sepsis in premature infants [79]. Noso- 
comial epidemics with vancomycin-resistant Entero- 
coccus faecium have been reported in oncologic patients 
[80,81], resulting in a mortality of 73% because of the 
absence of any therapeutic possibility [80]. Bacillus 
subtilis bacteremia occurred in four of 20 (oncologic) 
patients, but was also reported in other severely sick 
patients [63,83,83]. An unusual case of food poisoning 
with Staphylococcus aureus in combination with Bacillus 
cereus and Bacillus subtilis has been described. It has been 
speculated that very large numbers of bacteria may 
accelerate the manifestations of food poisoning [84]. As 
there is no evidence that Bacillus subtilis tablets are 
effective, their use must be restricted [62]. Although the 
incidence of infections remains extremely low, the idea 
arises that lactic acid bacteria may become pathogenic 
under certain circumstances [76]. 
Resistance or plasmid transfer 
If a bacterial biotherapeutic agent is used simul- 
taneously with an antibiotic, the biotherapeutic agent 
must be resistant to the antibiotic. However, transfer of 
genetic material from biotherapeutic agents to the 
commensal or pathogenic flora would have catastrophic 
consequences [9]. Gene transfer has been reported 
between enterococci in the gastrointestinal tract of 
experimental rats [ a ] .  Plasmid transfer from Lacto- 
bacillus reuteri to Enterococcus faecium and from Entero- 
coccus faecium to Enterococcus faecalis has been reported 
[9]. Many Enterococcus faecium strains have plasmids 
which are resistant to multiple antibiotics, including 
vancomycin [9]. In 1994, a biotherapeutic agent 
containing Enterococcus faecium SF 68 was taken off 
the Belgian market, because of reported nosocomial 
vancomycin-resistant infections. The induction of p- 
lactamase production in anaerobic bacteria was re- 
ported as a complication of the prevention of diarrhea 
associated with the administration of ceftriaxone (in 
other words, the resistance to the antibiotic was 
taken over by the anaerobic bacteria) [86]. Resistance 
to cephalosporins and macrolides was induced in a 
combination of four strains of Bacillus subtilis bacteria 
[63]. Azide-resistant Bacillus subtilis mutants have been 
reported [86]. 
Older publications report multiresistant Bacillus 
cereus [87] and Enterococcusfaecium [55]. At least one 
plasmid can be isolated fiom 80% of the Bacillus cereus 
strains, and can be transferred to Bacillus subtilis, where 
it is retained [88]. A transfer of macrolide-lincosamide- 
streptogramin B resistance between Clostridium d@cile 
and Bacillus subtilis, and vice versa, has been described 
without plasmid DNA being found [89]. 
An account of an epidemic of multiresistant Entero- 
coccus faecium with transferable vancomycin resistance 
was recently published [81]. The increase in 
vancomycin-resistant enterococci may be associated 
with the possible use of bacterial preparations which are 
administered orally to animals and humans. The 
association of enterococci (even if they are not 
intrinsically vancomycin resistant) with lactobacilli 
(which are intrinsically vancomycin-resistant) makes it 
difficult to detect vancomycin-resistant enterococci in 
biotherapeutic agents [89]. The vancomycin resistance 
of lactobacilli is chromosomal and not plasmid 
mediated, and, therefore, the risk of transmission to 
other organisms is small [lo]. Enterococci are com- 
mensal organisms with a potential virulence [90]. 
The safety and the long-term effects of bacterial 
biotherapeutic agents on antibiotic resistance must be 
thoroughly investigated before large-scale use can be 
recommended [9]. Because of these side effects, the 
benefit/risk ratio of pharmaceutical bacterial biother- 
apeutic agents in the prevention of antibiotic-associated 
diarrhea should be carefully considered. 
Induced arthritis and immunodepressive effect of the 
peptidoglycan present in the cell membrane of 
Gram-positive bacteria 
Cell membranes of streptococci and lactobacilli may 
cause chronic polyarthritis in men [91]. A Gram- 
positive intestinal flora, including bifidobacteria, 
Lactobacillus casei strain GG and Lactobacillus acidophilus, 
aggravates the consequences of such an induced 
arthritis in rats [92]. This is presumably due to peptido- 
glycan, an essential component of the Gram-positive 
bacterial cell wall that may cause an immunopathologic 
process [91,92]. Peptidoglycan contains D-glutamine 
and D-alanine, amino acids which do not exist as such 
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in nature. Mammals do not have proteases which can 
break down polypeptides containing D-amino acids. 
This can cause an irreversible .B-cell inactivation because 
of saturation of the membrane receptors. Reactive 
arthritis (Reiter’s syndrome) has been described in 
Shigella, Salmonella and Carnpylobacter infections via 
an indirect mechanism [93]. Lipopolysaccharides of 
Salmoriella spp. were detected in the joints of patients 
with reactive arthritis after a Salmonella infection [94]. 
This finding may possibly lim t the use of Gram-positive 
biotherapeutic agents in the tneatment of diarrhea caused 
by bacteria which increase the permeability of the 
intestinal wall, such as salmonellae. Administration of 
heat-killed Ldrtobacillur acidophiltrr is contraindicated in 
salmonellosis. 
CONCLUSIONS 
Biotherapeutic agents offer a large number of ther- 
apeutic benefits in the management of acute and 
chronic infectious diarrhea. A critical evaluation of their 
efficacy is a challenge, because many different micro- 
organisms have been used in different presentations and 
in different combinations. Most studies can be 
criticized (open, controlled without a placebo, too few 
patients, etc.). Although some in vitro studies provide 
very interesting results, the clinical utility of many 
bacterial biotherapeutic agents in vivo could frequently 
not be demonstrated. Some studies using Lmtobacillus 
rarei strain GG have provided promising data, although 
other studies provide contradictory results. All bacterial 
biotherapeutic agents still need to have their efficacy 
demonstrated in well-designed randomized double- 
blind studies before they can be recommended on a 
large scale. If bacterial biotherapeutic agents are to be 
used on a large scale in the fiiture, the eventual risk of 
transfer of their intrinsic resistance to most antibiotics 
should be thoroughly investigated. 
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